...
首页> 外文期刊>European review for medical and pharmacological sciences. >Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome
【24h】

Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome

机译:羟丁酸钠(GHB)的临床应用:从嗜睡症到酒精戒断综合征

获取原文
           

摘要

Gamma-hydroxybutyrate (GHB) is a short chain fatty acid endogenously produced within the central nervous system (CNS) and acts as a precursor and metabolite of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). Although, it is an illegal recreational drug of abuse, its sodium salt (sodium oxybate) has been utilized as a medication for a number of medical conditions. The first aim of this review was to focus on current applications of sodium oxybate for the treatment of narcolepsy, with a particular emphasis on the key symptoms of this disorder: cataplexy and excessive daytime sleepiness (EDS). Secondly, the effectiveness of sodium oxybate therapy for the treatment of alcohol withdrawal syndrome (AWS) and the maintenance of alcohol abstinence has been assessed. Nowadays, sodium oxybate is the first-line treatment for narcolepsy and it is highly effective in meliorating sleep architecture, decreasing EDS and the frequency of cataplexy attacks in narcoleptic patients. Sodium oxybate currently finds also application in the treatment of AWS and the maintenance of alcohol abstinence in alcoholics. Most of the studies evaluating the efficacy of GHB in the treatment of AWS use a dosage of 50 mg/kg divided in three or four administrations per day. Human studies showed that GHB (dose of 50 mg/kg, divided in three administrations per day) is capable to increase the number of abstinent days, reduce alcohol craving and decrease the number of drinks per day. However, there is limited randomized evidence and, thus, GHB cannot be reliably compared to clomethiazole or benzodiazepines. Some randomized data suggest that GHB is better than naltrexone and disulfiram regarding abstinence maintenance and prevention of craving in the medium term i.e. 3-12 months. It is recommended that GHB should be used only under strict medical supervision, since concerns about the abuse/misuse of the drug and the addiction potential have been arisen.
机译:γ-羟基丁酸酯(GHB)是在中枢神经系统(CNS)内源性产生的短链脂肪酸,是抑制性神经递质γ-氨基丁酸(GABA)的前体和代谢产物。尽管它是一种滥用的非法娱乐药物,但其钠盐(羟丁酸钠)已被用作许多医疗条件的药物。这篇综述的首要目的是着眼于羟丁酸钠在发作性睡病治疗中的当前应用,特别着重于该疾病的关键症状:瘫痪和白天过度嗜睡(EDS)。其次,评估了羟丁酸钠治疗酒精戒断综合征(AWS)和维持酒精戒断的有效性。如今,羟丁酸钠已成为发作性睡病的一线治疗方法,对缓解睡眠结构,降低EDS和发作性发作患者的脑瘫发作频率非常有效。目前,羟丁酸钠还发现可用于治疗AWS和维持酒精中毒者戒酒。大多数评估GHB在治疗AWS中疗效的研究均使用50 mg / kg的剂量,每天分为三或四次。人体研究表明,GHB(50 mg / kg的剂量,每天分三次服用)能够增加戒断天数,减少饮酒的欲望并减少每天的饮料数量。但是,随机证据有限,因此无法可靠地将GHB与氯苯甲咪唑或苯二氮卓类药物进行比较。一些随机数据表明,在中期(即3至12个月)内,在节欲维持和预防渴望方面,GHB优于纳曲酮和双硫仑。建议您仅在严格的医学监督下使用GHB,因为已经引起对药物滥用/滥用和成瘾性的担忧。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号